Could an arthritis drug lift depression in HIV patients?
NCT ID NCT05849038
First seen May 28, 2026
Summary
This study looks at whether inflammation in the brain causes symptoms like loss of interest and slow movement in depressed people with HIV. Sixty participants will receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks. Researchers will use brain scans and motivation tests to see if the drug improves these symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Grady Memorial Hospital
RECRUITINGAtlanta, Georgia, 30303, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
baricitinib (Olumiant)
What this could lead to
If it works, this could point toward a new treatment for depression in people with HIV by targeting inflammation.
What could go wrong
This is a small, early-phase study with only 60 participants. The drug may not improve symptoms, and side effects like infection risk are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.